| Literature DB >> 32367824 |
Diana Becerra1, Juan Castillo1, Braulio Insuasty2, Justo Cobo3, Christopher Glidewell4.
Abstract
An operationally simple and time-efficient approach has been developed for the synthesis of racemic N-substituted 3-(2-aryl-2-oxoethyl)-3-hydroxyindolin-2-ones by aEntities:
Keywords: 3-hydroxyindolinone; crystal structure; heterocyclic compounds; hydrogen bonding; isatin; molecular structure; supramolecular assembly; synthesis
Year: 2020 PMID: 32367824 PMCID: PMC7199199 DOI: 10.1107/S2053229620004143
Source DB: PubMed Journal: Acta Crystallogr C Struct Chem ISSN: 2053-2296 Impact factor: 1.172
Hydrogen bonds and related short intramolecular contacts (Å, °) for compounds (Ic)–(If), (IIa), (IIe) and (IIg)
Cg1, Cg2 and Cg3 represent the centroids of the C3A/C4–C7/C7A, C11–C16 and C13A/C14–C17/C17A rings, respectively.
|
|
| H⋯ |
|
| ||
|---|---|---|---|---|---|---|
| (I | O3—H3⋯O2i | 0.86 (2) | 2.10 (2) | 2.9487 (15) | 171.1 (18) | |
| C6—H6⋯O324ii | 0.95 | 2.41 | 3.297 (2) | 155 | ||
| C31—H31 | 0.99 | 2.48 | 3.312 (2) | 141 | ||
| C4—H4⋯ | 0.95 | 2.93 | 3.6101 (18) | 130 | ||
| C14—H14⋯ | 0.95 | 2.82 | 3.709 (2) | 156 | ||
| (I | O3—H3⋯O2v | 0.868 (18) | 1.918 (18) | 2.7630 (12) | 164.2 (18) | |
| C7—H7⋯O32vi | 0.95 | 2.44 | 3.3343 (16) | 157 | ||
| C1—H1 | 0.99 | 2.96 | 3.8375 (14) | 149 | ||
| (I | O3—H3⋯N321vii | 0.897 (17) | 1.897 (17) | 2.7915 (14) | 174.9 (15) | |
| C4—H4⋯O3v | 0.95 | 2.46 | 3.3842 (14) | 164 | ||
| C7—H7⋯O32viii | 0.95 | 2.51 | 3.3719 (14) | 150 | ||
| C325—H325⋯O2ix | 0.95 | 2.32 | 3.2578 (15) | 171 | ||
| C322—H322⋯ | 0.95 | 2.68 | 3.5294 (14) | 149 | ||
| (I | O13—H13⋯O22 | 0.874 (17) | 1.912 (17) | 2.7794 (12) | 171.1 (17) | |
| O23—H23⋯O12 | 0.874 (17) | 1.912 (17) | 2.7794 (12) | 171.1 (17) | ||
| C131–H13 | 0.99 | 2.35 | 3.3075 (16) | 161 | ||
| C147—H147⋯O141x | 0.95 | 2.56 | 3.4776 (18) | 163 | ||
| C231—H23 | 0.99 | 2.37 | 3.3107 (15) | 159 | ||
| C242—H24 | 0.99 | 2.53 | 3.4889 (19) | 163 | ||
| C142—H14 | 0.99 | 2.53 | 3.3289 (15) | 137 | ||
| (II | C15—H15⋯O32xi | 0.95 | 2.49 | 3.278 (3) | 141 | |
| (II | C14—H14⋯O2xii | 0.95 | 2.32 | 3.234 (3) | 161 | |
| C16—H16⋯O2xiii | 0.95 | 2.45 | 3.230 (2) | 140 | ||
| C326—H326⋯O2xiv | 0.95 | 2.58 | 3.494 (2) | 162 | ||
| C6—H6⋯ | 0.95 | 2.64 | 3.566 (2) | 165 | ||
| (II | C5—H5⋯O2xv | 0.95 | 2.59 | 3.5058 (19) | 161 | |
| C323—H323⋯ | 0.95 | 2.93 | 3.744 (3) | 145 |
Symmetry codes: (i) −x + , −y + , −z + 1; (ii) x, y − 1, z; (iii) x, −y + 1, z + ; (iv) −x + , −y + , −z + 1; (v) −x + 1, −y + 1, −z + 1; (vi) −x, −y + 1, −z + 2; (vii) x, y + 1, z; (viii) −x + 1, −y + 1, −z; (ix) −x, −y + 1, −z + 1; (x) −x, −y, −z + 1; (xi) −x + 1, y − , −z + ; (xii) x + , −y + , z − ; (xiii) x − , −y + , z − ; (xiv) x + , −y + , z + ; (xv) x − , y, −z + ; (xvi) −x + 1, y + , −z + .
Figure 1The molecular structure of the R enantiomer of compound (Ic), showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 30% probability level.
Figure 2The molecular structure of the R enantiomer of compound (Id), showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 30% probability level.
Figure 3The molecular structure of the R enantiomer of compound (Ie), showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 30% probability level.
Figure 4The R enantiomers of the two independent molecules of compound (If), showing the atom-labelling schemes for (a) molecule 1 and (b) molecule 2. Displacement ellipsoids are drawn at the 30% probability level.
Figure 5The molecular structure of compound (IIa), showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 30% probability level.
Figure 6The molecular structure of compound (IIc), showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 30% probability level.
Figure 7The molecular structure of compound (IIe), showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 30% probability level.
Figure 8The molecular structure of compound (IIg), showing the atom-labelling scheme and the disorder of the thiophene unit. The major-disorder component is drawn using full lines and the minor-disorder component has been drawn using broken lines. Displacement ellipsoids are drawn at the 30% probability level.
Figure 9The molecular structure of compound (IIh), showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 30% probability level.
Selected torsion angles (°) for compounds (Ic)–(If)
| Parameter | (I | (I | (I | (I | (I |
|---|---|---|---|---|---|
| ( | ( | ||||
| C | 103.75 (16) | 102.09 (12) | 95.90 (12) | 119.11 (13) | 108.60 (13) |
| N | −28.5 (2) | −40.32 (15) | −76.98 (13) | −54.19 (16) | −27.57 (17) |
| N | −126.14 (13) | −133.07 (10) | −124.96 (9) | −123.72 (10) | −126.04 (10) |
| C | 52.57 (17) | 58.79 (13) | 61.83 (12) | 50.92 (13) | 51.93 (13) |
| C3—C31—C32—C321 | −176.52 (13) | 179.12 (10) | |||
| C3—C31—C32—C324 | −179.45 (10) | ||||
| C31—C32—C321—C322 | 175.64 (14) | −176.22 (10) | |||
| C31—C32—C324—C323 | −149.73 (12) | ||||
| C | −174.30 (10) | −174.80 (10) | |||
| C | 176.61 (10) | 178.65 (11) |
Selected torsion angles (°) for compounds (IIa), (IIc), (IIe), (IIg) and (IIh)
| Parameter | (II | (II | (II | (II | (II |
|---|---|---|---|---|---|
| C2—N1—C1—C11 | 111.4 (2) | 102.92 (13) | 90.35 (19) | 94.94 (16) | 98.83 (15) |
| N1—C1—C11—C12 | −41.8 (3) | −61.57 (14) | −1.1 (2) | −65.13 (18) | −62.18 (16) |
| N1—C2—C3—C31 | −176.39 (19) | −177.72 (10) | 179.61 (15) | 177.30 (12) | −179.37 (12) |
| C2—C3—C31—C32 | 176.1 (2) | 178.62 (11) | −178.71 (16) | 178.91 (13) | 177.52 (13) |
| C3—C31—C32—C321 | −176.0 (2) | 172.77 (11) | 177.57 (14) | ||
| C3—C31—C32—C322 | −175.99 (14) | ||||
| C3—C31—C32—C324 | 179.55 (16) | ||||
| C31—C32—C321—C322 | −178.2 (2) | 169.40 (10) | 175.80 (12) | ||
| C31—C32—C322—S321 | 167.55 (10) | ||||
| C31—C32—C324—C323 | 173.76 (15) |
Figure 10Part of the crystal structure of compound (Ic), showing the formation of a chain of rings built from O—H⋯O, C—H⋯O and C—H⋯π(arene) hydrogen bonds. Hydrogen bonds are drawn as dashed lines and, for the sake of clarity, H atoms not involved in the motifs shown have been omitted.
Figure 11Part of the crystal structure of compound (Id), showing the formation of a chain of rings built from O—H⋯O and C—H⋯O hydrogen bonds. Hydrogen bonds are drawn as dashed lines and, for the sake of clarity, H atoms not involved in the motifs shown have been omitted.
Figure 12Part of the crystal structure of compound (Ie), showing the formation of a chain of rings running parallel to the [010] direction and built from O—H⋯N and C—H⋯π(arene) hydrogen bonds. Hydrogen bonds are drawn as dashed lines and, for the sake of clarity, H atoms not involved in the motifs shown have been omitted.
Figure 13Part of the crystal structure of compound (Ie), showing the formation of a chain of rings running parallel to the [001] direction and built from two types of C—H⋯O hydrogen bonds. Hydrogen bonds are drawn as dashed lines and, for the sake of clarity, H atoms not involved in the motifs shown have been omitted.
Figure 14Part of the crystal structure of compound (Ie), showing the formation of a chain of rings running parallel to the [100] direction and built from two types of C—H⋯O hydrogen bonds. Hydrogen bonds are drawn as dashed lines and, for the sake of clarity, H atoms not involved in the motifs shown have been omitted.
Figure 15Part of the crystal structure of compound (If), showing the linking of the two independent molecules by two independent O—H⋯O hydrogen bonds. Hydrogen bonds are drawn as dashed lines and, for the sake of clarity, H atoms not involved in the motifs shown have been omitted.
Figure 16Part of the crystal structure of compound (If), showing the formation of a chain of rings running parallel to the [100] direction and built from O—H⋯O and C—H⋯O hydrogen bonds. Hydrogen bonds are drawn as dashed lines and, for the sake of clarity, H atoms not involved in the motifs shown have been omitted.
Figure 17Part of the crystal structure of compound (If), showing the formation of a chain of rings running parallel to the [010] direction and built from O—H⋯O, C—H⋯O and C—H⋯π(arene) hydrogen bonds. Hydrogen bonds are drawn as dashed lines and, for the sake of clarity, H atoms not involved in the motifs shown have been omitted.
Figure 18Part of the crystal structure of compound (IIa), showing the formation of a hydrogen-bonded chain running parallel to [010]. Hydrogen bonds are drawn as dashed lines and, for the sake of clarity, H atoms not involved in the motif shown have been omitted.
Figure 19Part of the crystal structure of compound (IIg), showing the formation of a hydrogen-bonded chain running parallel to [100]. Hydrogen bonds are drawn as dashed lines and, for the sake of clarity, the minor-disorder component and H atoms not involved in the motif shown have been omitted.
Figure 20Part of the crystal structure of compound (IIe), showing the formation of a sheet built from three C—H⋯O hydrogen bonds and lying parallel to (010). Hydrogen bonds are drawn as dashed lines and, for the sake of clarity, H atoms not involved in the motifs shown have been omitted.
Figure 21Part of the crystal structure of compound (IIh), showing the formation of a chain of π-stacked dimers running parallel to the [100] direction. The Cl⋯(ring centroid) contacts are shown as tapered lines and, for the sake of clarity, H atoms have all been omitted.
Experiments were carried out at 100 K with Mo Kα radiation using a Bruker D8 Venture diffractometer. Absorption was corrected for by multi-scan methods (SADABS; Bruker, 2016 ▸), except for (IIa) and (IIe), where TWINABS (Bruker, 2012) was used.
| (I | (I | (I | |
|---|---|---|---|
| Crystal data | |||
| Chemical formula | C24H21NO4 | C25H24N2O3 | C22H18N2O3 |
|
| 387.42 | 400.46 | 358.38 |
| Crystal system, space group | Monoclinic, | Triclinic, | Triclinic, |
|
| 18.7572 (14), 13.2095 (10), 16.750 (2) | 9.1028 (8), 10.6434 (9), 11.2539 (10) | 7.8838 (5), 10.1766 (8), 11.8719 (9) |
| α, β, γ (°) | 90, 105.374 (5), 90 | 88.988 (3), 68.422 (3), 81.352 (3) | 87.554 (3), 75.996 (2), 69.428 (2) |
|
| 4001.7 (6) | 1001.55 (15) | 864.30 (11) |
|
| 8 | 2 | 2 |
| μ (mm−1) | 0.09 | 0.09 | 0.09 |
| Crystal size (mm) | 0.14 × 0.13 × 0.10 | 0.23 × 0.19 × 0.16 | 0.25 × 0.16 × 0.06 |
| Data collection | |||
|
| 0.908, 0.991 | 0.946, 0.986 | 0.949, 0.994 |
| No. of measured, independent and observed [ | 18506, 4768, 3469 | 41110, 4590, 4033 | 55488, 4333, 3760 |
|
| 0.051 | 0.037 | 0.045 |
| (sin θ/λ)max (Å−1) | 0.659 | 0.650 | 0.670 |
| Refinement | |||
|
| 0.047, 0.110, 1.02 | 0.038, 0.098, 1.05 | 0.038, 0.101, 1.07 |
| No. of reflections | 4768 | 4590 | 4333 |
| No. of parameters | 266 | 276 | 247 |
| No. of restraints | 0 | 0 | 0 |
| H-atom treatment | H atoms treated by a mixture of independent and constrained refinement | H atoms treated by a mixture of independent and constrained refinement | H atoms treated by a mixture of independent and constrained refinement |
| Δρmax, Δρmin (e Å−3) | 0.30, −0.26 | 0.30, −0.22 | 0.41, −0.22 |
| (I | (II | (II | |
|---|---|---|---|
| Crystal data | |||
| Chemical formula | C24H19NO5 | C23H16FNO2 | C24H19NO3 |
|
| 401.40 | 357.37 | 369.40 |
| Crystal system, space group | Triclinic, | Monoclinic, | Monoclinic, |
|
| 11.8136 (7), 12.4987 (10), 13.5976 (11) | 7.6021 (6), 20.4880 (13), 10.9319 (7) | 4.9743 (2), 29.1957 (13), 12.4406 (6) |
| α, β, γ (°) | 93.084 (3), 101.883 (2), 95.055 (2) | 90, 96.986 (3), 90 | 90, 100.914 (2), 90 |
|
| 1951.7 (3) | 1690.0 (2) | 1774.05 (14) |
|
| 4 | 4 | 4 |
| μ (mm−1) | 0.10 | 0.10 | 0.09 |
| Crystal size (mm) | 0.25 × 0.16 × 0.06 | 0.14 × 0.14 × 0.10 | 0.45 × 0.06 × 0.04 |
| Data collection | |||
|
| 0.957, 0.994 | 0.917, 0.990 | 0.948, 0.996 |
| No. of measured, independent and observed [ | 125792, 9691, 8134 | 3896, 3896, 2995 | 54500, 4142, 3643 |
|
| 0.049 | N/A | 0.048 |
| (sin θ/λ)max (Å−1) | 0.667 | 0.652 | 0.653 |
| Refinement | |||
|
| 0.039, 0.106, 1.08 | 0.058, 0.134, 1.05 | 0.037, 0.095, 1.06 |
| No. of reflections | 9691 | 3896 | 4142 |
| No. of parameters | 547 | 245 | 254 |
| No. of restraints | 0 | 0 | 0 |
| H-atom treatment | H atoms treated by a mixture of independent and constrained refinement | H-atom parameters constrained | H-atom parameters constrained |
| Δρmax, Δρmin (e Å−3) | 0.38, −0.24 | 0.29, −0.28 | 0.27, −0.23 |
| (II | (II | (II | |
|---|---|---|---|
| Crystal data | |||
| Chemical formula | C22H16N2O2 | C21H15NO2S | C23H15Cl2NO2 |
|
| 340.37 | 345.40 | 408.26 |
| Crystal system, space group | Monoclinic, | Orthorhombic, | Triclinic, |
|
| 7.3457 (6), 18.0675 (16), 13.1813 (13) | 17.5058 (14), 8.8163 (6), 21.2092 (16) | 8.2010 (6), 9.7629 (7), 12.1740 (9) |
| α, β, γ (°) | 90, 105.994 (3), 90 | 90, 90, 90 | 76.755 (3), 87.675 (3), 76.211 (3) |
|
| 1681.7 (3) | 3273.4 (4) | 921.34 (12) |
|
| 4 | 8 | 2 |
| μ (mm−1) | 0.09 | 0.21 | 0.37 |
| Crystal size (mm) | 0.16 × 0.15 × 0.12 | 0.15 × 0.07 × 0.05 | 0.40 × 0.16 × 0.07 |
| Data collection | |||
|
| 0.878, 0.990 | 0.942, 0.989 | 0.924, 0.974 |
| No. of measured, independent and observed [ | 4167, 4167, 3281 | 32005, 4154, 3280 | 51788, 4558, 3867 |
|
| N/A | 0.065 | 0.053 |
| (sin θ/λ)max (Å−1) | 0.668 | 0.672 | 0.667 |
| Refinement | |||
|
| 0.044, 0.121, 1.09 | 0.038, 0.092, 1.04 | 0.032, 0.082, 1.11 |
| No. of reflections | 4167 | 4154 | 4558 |
| No. of parameters | 237 | 239 | 253 |
| No. of restraints | 0 | 10 | 0 |
| H-atom treatment | H-atom parameters constrained | H-atom parameters constrained | H-atom parameters constrained |
| Δρmax, Δρmin (e Å−3) | 0.29, −0.19 | 0.29, −0.31 | 0.44, −0.34 |
Computer programs: APEX3 (Bruker, 2018 ▸), SAINT (Bruker, 2017 ▸), SHELXT2014 (Sheldrick, 2015a ▸), SHELXL2014 (Sheldrick, 2015b ▸) and PLATON (Spek, 2020 ▸).